In short
Milademetan is an investigational drug being studied in clinical trials for various types of cancer, particularly acute myeloid leukemia (AML) and advanced solid tumors. As an oral MDM2 inhibitor, it works by targeting a specific protein involved in cancer cell growth. This article summarizes key information from several clinical trials evaluating milademetan's safety, efficacy, and potential as a new cancer therapy.
At a glance
- Drug Name
- Milademetan (also known as DS-3032b)
- Drug Class
- Oral MDM2 inhibitor
- Primary Indications
- Acute Myeloid Leukemia (AML), Advanced Solid Tumors
- Administration
- Oral capsules, various dosing schedules
- Key Clinical Trials
- NCT01877382, NCT02319369, NCT03552029, NCT03671564, NCT06090318
- Combination Studies
- With azacitidine, quizartinib, atezolizumab, low-dose cytarabine
- Primary Outcomes
- Safety, tolerability, maximum tolerated dose, pharmacokinetics
- Secondary Outcomes
- Objective response rate, progression-free survival, overall survival
- Common Side Effects
- Nausea, fatigue, decreased appetite, changes in blood cell counts
- Current Status
- Investigational; not yet approved for general use
What is Milademetan?
Milademetan, also known as DS-3032b or RAIN-32, is an experimental drug being studied for the treatment of various types of cancer. It belongs to a class of drugs called MDM2 inhibitors, which are designed to target specific proteins involved in cancer growth.
How Does Milademetan Work?
Milademetan works by blocking a protein called MDM2. This protein normally helps control the levels of another important protein called p53, which is known as the "guardian of the genome" because it helps prevent cancer by stopping damaged cells from dividing. In some cancers, there's too much MDM2, which can prevent p53 from doing its job. By blocking MDM2, milademetan allows p53 to become active again and help fight cancer cells.
What Conditions Does Milademetan Treat?
Milademetan is being studied for the treatment of several types of cancer, including:
- Advanced solid tumors: These are cancers that form solid masses in the body, such as in the lungs, breast, or colon.
- Lymphomas: Cancers that start in cells of the immune system.
- Acute Myeloid Leukemia (AML): A type of blood cancer that affects the bone marrow.
- Myelodysplastic Syndrome (MDS): A group of disorders where the bone marrow doesn't produce enough healthy blood cells.
- Advanced or metastatic breast cancer: Specifically for patients with certain genetic mutations (GATA3 mutations).
Clinical Trials and Research
Milademetan is currently being studied in various clinical trials to determine its safety and effectiveness. These trials are testing the drug:
- Alone in different doses and schedules.
- In combination with other cancer drugs like azacitidine for leukemia.
- With quizartinib for a specific type of AML.
- Combined with atezolizumab for solid tumors with specific genetic changes.
- With fulvestrant for breast cancer patients with GATA3 mutations.
Researchers are looking at how well the drug works, how safe it is, and how it affects the body (pharmacokinetics and pharmacodynamics).
How is Milademetan Administered?
Milademetan is taken orally as capsules. The dosage and schedule can vary depending on the specific study and condition being treated. Some common dosing schedules include:
- Daily for 3-14 days, followed by a rest period.
- Three consecutive days every two weeks.
The capsules come in different strengths (5 mg, 20 mg, 80 mg, and 200 mg) and are sometimes combined to achieve the right dose.
Potential Side Effects
As with any medication, milademetan can cause side effects. In clinical trials, researchers are closely monitoring for:
- Changes in blood cell counts
- Liver function abnormalities
- Gastrointestinal issues (nausea, vomiting, diarrhea)
- Fatigue
- Effects on heart rhythm (QT prolongation)
It's important to note that not all patients will experience these side effects, and the severity can vary. Researchers are working to understand and manage these potential side effects.
Drug Interactions
Milademetan interacts with enzymes in the liver called CYP3A4. This means it can potentially interact with other medications that affect these enzymes. Specific studies have looked at interactions with drugs like itraconazole and posaconazole (antifungal medications). Patients should always inform their healthcare providers about all medications they are taking.
Future Research and Potential
Milademetan is still in the early stages of research, but it shows promise for treating various types of cancer, especially those where the p53 pathway is disrupted. Ongoing and future studies will help determine:
- Which patients are most likely to benefit from the drug
- The best dosing schedules and combinations with other treatments
- Long-term safety and effectiveness
As research continues, milademetan may become an important new option in the fight against cancer.